M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals

doi:10.3748/wjg.v26.i21.2864

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7952)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

544

WORD

209

HTML

4106

Figures (1-3)

348

Tables (1-5)

243

Sum=5450

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

958

Download

1544

Sum=2502

Jun 7, 2020 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Jun 7, 2020; 26(21): 2864-2876
Published online Jun 7, 2020. doi: 10.3748/wjg.v26.i21.2864

Table 1 Patients’ characteristics at baseline and sustained virologic response 12

Measures	Baseline	SVR12	P value
Age (yr)	52.3 ± 10.7
Gender	40 (50%) males and 40 (50%) females
BMI	28 ± 5.4
HCV RNA (log copies/mL)	6.0 ± 0.7	Non-detectable	0.000^b
Platelets count (× 10³/mL)	220.3 ± 65.3	245.3 ± 77.8	0.005^b
ALT (IU/L)	40.5 (29-54)	32 (26-38)	< 0.001^b
AST (IU/L)	39 (29-51)	30 (24-37)	< 0.001^b
ALP (IU/L)	138.5 (95.5-196)	107 (86-141)	< 0.001^b
Albumin (g/dL)	3.8 ± 0.3	4.2 ± 0.4	< 0.001^b
Total bilirubin (mg/dL)	0.7 (0.5-0.8)	0.7 (0.5-0.95)	0.8
Creatinine (mg/dL)	0.86 ± 0.19	0.75 ± 0.23	0.002^b
INR	1.06 ± 0.09	1.08 ± 0.15	0.222
AFP (ng/mL)	4.5 ± 2.1	3.7 ± 1.9	0.128
LSM (kPa)	11.4 ± 4.5	9.5 ± 3.3	0.002^b
FIB-4 score	1.8 ± 0.5	1.3 ± 0.7	< 0.001^b
PAPAS index	2.2 ± 0.5	2.1 ± 0.3	0.010^a
Serum M2BPGi (ng/mL)	9 ± 3.8	6.7 ± 2.3	< 0.001^b

The values are expressed as mean ± SD or median (IQR).

^aP < 0.05.

^bP < 0.01. SVR: Sustained virologic response; WBC: White blood cell count; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; INR: International normalized ratio; AFP: Alpha fetoprotein; LSM; Liver stiffness measurement; M2BPGi: Mac-2 binding protein glycosylation isomer.

Table 2 Liver stiffness measurements of all patients at baseline and sustained virologic response 12

Total baseline	Changes in the fibrosis grade at SVR12
Total baseline	F0-1 (%)	F2 (%)	F3 (%)	F4 (%)
F0-1 29 (36.3%)	23 (79.3)	5 (17.2)	1 (3.4)	0 (0.0)
F2 20 (25%)	10 (50)	10 (50)	0 (0.0)	0 (10)
F3 5 (6.3%)	1 (20)	2 (40)	1 (20)	1 (20)
F4 26 (32.5%)	1 (3.8)	6 (23.1)	4 (15.4)	15 (57.7)
Total SVR12	35 (43.7)	23 (28.7)	6 (7.5)	16 (20)

Total patients number = 80. The values are expressed as numbers (%). SVR: Sustained virologic response.

Table 3 Non-invasive assessment data obtained at baseline and sustained virologic response 12 from patients stratified according to the fibrosis grade

Parameter					P value
Baseline (Total n = 80)	F0-1 (n = 29)	F2 (n = 20)	F3 (n = 5)	F4 (n = 26)
LSM (kPa)	5.9 ± 0.6	7.8 ± 0.5	10.8 ± 1.2	20.6 ± 7.7	< 0.001^b
FIB-4 score	1.7 ± 1.4	1.4 ± 0.7	1.8 ± 0.4	2.3 ± 1.5	0.108
PAPAS index	2.1 ± 0.4	2.2 ± 0.6	2.3 ± 0.3	2.3 ± 0.5	0.303
Serum M2BPGi (ng/mL)	4.5 ± 2.2	5.3 ± 2.8	9.4 ± 4	14.5 ± 6.7	0.001^b
SVR 12 (Total n = 80)	F0-1 (n = 35)	F2 (n = 23)	F3 (n = 6)	F4 (n = 16)
LSM (kPa)	5.8 ± 1.2	7.6 ± 0.6	9.9 ± 0.8	15 ± 2.3	< 0.001^b
FIB-4 score	1.1 ± 0.5	1.5 ± 1	1.3 ± 0.6	1.6 ± 0.5	0.075
PAPAS index	2 ± 0.3	2.1 ± 0.3	2.1 ± 0.3	2.3 ± 0.3	0.069
Serum M2BPGi (ng/mL)	3.4 ± 1.6	4.9 ± 2.1	12.7 ± 5.1	13.3 ± 5.2	0.001^b

^bP < 0.01. The values are expressed as mean ± SD. SVR: Sustained virologic response; LSM: Liver stiffness measurement; M2BPGi: Mac-2 binding protein glycosylation isomer.

Table 4 Correlations of serum Mac-2 binding protein glycosylation isomer levels with laboratory data

Variables	Baseline		SVR12
Variables	r	P value	r	P value
Age	0.050	0.662	0.107	0.346
BMI	-0.007	0.951	0.057	0.617
HCV RNA	0.043	0.702	0.025	0.827
Hb	0.143	0.205	0.131	0.246
WBC	0.047	0.677	-0.152	0.178
Platelets count	-0.118	0.297	-0.299	0.007^b
ALT	-0.090	0.425	-0.129	0.256
AST	-0.227	0.043^a	0.006	0.961
ALP	-0.024	0.831	0.106	0.350
Albumin	0.016	0.888	0.070	0.535
Total bilirubin	0.268	0.016^a	0.111	0.326
Creatinine	0.158	0.162	0.088	0.439
INR	0.063	0.582	0.220	0.049^a
AFP	-0.098	0.388	0.026	0.822

^aP < 0.05.

^bP < 0.01. SVR: Sustained virologic response; BMI: Body mass index; Hb: Haemoglobin; WBC: White blood cell count; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; INR: International normalized ratio; AFP: Alpha fetoprotein.

Table 5 Correlations between non-invasive assessment methods at baseline and sustained virologic response 12

Variables		LSM	Serum M2BPGi	FIB-4 score
At baseline
Serum M2BPGi level	r	0.453
Serum M2BPGi level	P value	< 0.001^b
FIB-4 score	r	0.328	-0.099
FIB-4 score	P value	0.003^b	0.384
PAPAS index	r	0.110	-0.049	0.444
PAPAS index	P value	0.330	0.664	< 0.001^b
At SVR12
Serum M2BPGi level	r	0.517
Serum M2BPGi level	P value	< 0.001^b
FIB-4 score	r	0.231	0.188
FIB-4 score	P value	0.039^a	0.095
PAPAS index	r	0.328	0.185	0.188
PAPAS index	P value	0.003^b	0.100	0.095

^aP < 0.05.

^bP < 0.01. SVR: Sustained virologic response; LSM: Liver stiffness measurement; M2BPGi: Mac-2 binding protein glycosylation isomer.

Citation: Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J Gastroenterol 2020; 26(21): 2864-2876
URL: https://www.wjgnet.com/1007-9327/full/v26/i21/2864.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i21.2864